InvestorsHub Logo
Followers 21
Posts 9598
Boards Moderated 0
Alias Born 07/13/2017

Re: proffetti post# 2025

Wednesday, 03/20/2019 8:57:52 AM

Wednesday, March 20, 2019 8:57:52 AM

Post# of 2495
From the earnings.

Operating expenses for the full-year 2018 were $26.9 million, compared to $33.1 million for the full-year 2017, a decrease of approximately 19%. This decrease was due primarily to a $5.7 million, or 23% decrease, in R&D expense, while SG&A expenses remained unchanged.

26.9M per year cash burn, R&D investment declining. SG&A for a compnay not selling anything.

What do you think happens in 9 months, should an FDA miracle not happen?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CRMD News